Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTn I and BNP levels / 中国临床药理学与治疗学

ABSTRACT

AIM: To investigate the effect of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cardiac troponin I (CTnl) and B-type brain natriuretic peptide (BNP) levels. METHODS: Seventy patients with HFrEF admitted to our hospital from January 2020 to October 2021 were selected and divided, using random number table method, into control group (35 cases, conventional treatment + sakubatril valsartan) and observation group (35 cases, conventional treatment + sakubatril valsartan + dagliflozin). The treatment effect, myocardial markers (serum cTnl, BNP), exercise capacity (6 min walking experiment), myocardial remodeling-related indexes [(left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic internal diameter (LVESD), left ventricular ejection fraction (LVEF)] and adverse effects were compared between the two groups. RESULTS: The total effective rate of treatment in the observation group was lower than that in the control group (P 0.05); the changing trends of serum BNP and cTnl expressions were the same in the two groups at 3 months and 6 months of treatment, and the serum BNP and cTnl expressions of patients in the observation group were lower than those in the control group (P 0.05). CONCLUSION: The combination of sakubatril valsartan and dagliflozin is effective for patients with HFrEF, and can effectively regulate serum cTnl and BNP levels with low adverse reactions.